Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Demonstrating that a growth hormone secretagogue can fully normalize growth in GHRH-deficient conditions provides compelling evidence for its therapeutic potential. This study by Alba, Fintini, Sagazio, and colleagues tested whether once-daily administration of CJC-1295 could normalize growth in GHRH knockout mice, a model of complete growth hormone-releasing hormone deficiency.

The researchers administered CJC-1295 once daily to GHRH knockout mice and monitored growth parameters including body weight, length, and growth hormone/IGF-1 levels over time. The knockout model provided a stringent test of CJC-1295's ability to fully restore growth hormone axis function.

The results showed that once-daily CJC-1295 fully normalizes growth in GHRH-deficient mice, demonstrating that the long-acting analog can completely compensate for the absence of natural GHRH. This complete normalization of growth confirmed CJC-1295's effectiveness as a potent and sustained growth hormone-releasing agent.

This study provides strong preclinical evidence for CJC-1295's ability to restore growth hormone function in deficiency states. For patients with growth hormone insufficiency, the demonstration that a once-daily peptide can fully normalize growth hormone activity supports CJC-1295 as an effective and convenient therapeutic option.